Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
Join the club for FREE to access the whole archive and other member benefits.
Chief Scientific Officer at Senolytic Therapeutics.
Tim has extensive experience in aging and age-related diseases such as cancer and diabetes. He has carried out multiple genetic and drug screens to identify novel diabetes and cancer therapeutics during his academic career which has inspired him to pursue a career in industry. Tim has a Ph.D. in Cell and Molecular Biology at the University of Pennsylvania and outstanding postdoctoral experience at the prestigious Spanish National Cancer Center (CNIO) in Madrid, Spain.
Visit website: https://www.crunchbase.com/person/timothy-cash
See also: Senolytic Therapeutics (Senolytx) - Pharmaceutical company that develops a novel class of medicines by targeting damaged cells.
Details last updated 10-Sep-2020
General feeling that failures are bound to happen - but that their approaches can succeed
Searching the genomes of centenarians these genes are most clearly associated with lifespan. 20 ...